About Xennex
Xennex is a Healthcare company based in Cambridge (United States) founded in 2003, and was acquired by Lineage Cell Therapeutics in April 2012. Bio-medical research services and genomic databases are provided by XenneX. It operates in the Healthcare and Technology sectors. The company was acqui-hired. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Human Longevity, DNAnexus and Seven Bridges Genomics; 3 of its 3 listed competitors have raised funding.
Company details
XenneX provides services and tools for bio-medical research. It offers GeneCards - a searchable, integrated database of human genes to get genomic related information on all known and predicted human genes. Its GeneCards Suite includes GeneDecks - to explore sets of GeneCards genes; GeneALaCart that generates a file of GeneCards annotations for list of genes; GeneLoc that presents an integrated map for each human chromosome based on data integrated by the GeneLoc algorithm; GeneNote - a database of human genes and their expression profiles in healthy tissues; GeneAnnot that provides an annotation of Affymetrix probe-sets; and GeneTide, an automated system for human transcripts (mRNA and ESTs). It also offers PanDaTox, a database that aims at identifying genes and intergenic regions that are unclonable in E. coli.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Website xennexinc.com
- Acquired by Lineage Cell Therapeutics (Apr 2012)
- Investors
- Acquired byLineage Cell Therapeutics
(Apr 2012)
Investors in Xennex
Xennex has secured backing from 1 investor. Prominent investors backing the company include Lineage Cell Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Lineage Cell Therapeutics is focused on developing allogeneic cell therapies. | 1990 | lineagecell.com | Carlsbad, United States |
Investor details for Xennex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Xennex
2 dated milestones of Xennex across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Xennex is founded.
- Exit Acquired by Lineage Cell Therapeutics.
Competitors of Xennex
Xennex has 3 listed competitors in our database, 3 of them funded. They include Human Longevity, DNAnexus and Seven Bridges Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humanlongevity.com | 2013 | San Diego, United States | $376.72M | 83 | Genomics data and cell therapy-based diagnostic and therapeutic solutions | |
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. |
Detailed competitors of Xennex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Xennex (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xennex
Xennex was founded in 2003.
Xennex is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
XenneX provides services and tools for bio-medical research. It offers GeneCards - a searchable, integrated database of human genes to get genomic related information on all known and predicted human genes. Its GeneCards Suite includes GeneDecks - to explore sets of GeneCards genes; GeneALaCart that generates a file of GeneCards annotations for list of genes; GeneLoc that presents an integrated map for each human chromosome based on data integrated by the GeneLoc algorithm; GeneNote - a database of human genes and their expression profiles in healthy tissues; GeneAnnot that provides an annotation of Affymetrix probe-sets; and GeneTide, an automated system for human transcripts (mRNA and ESTs). It also offers PanDaTox, a database that aims at identifying genes and intergenic regions that are unclonable in E. coli.
Xennex's top competitors include DNAnexus, Human Longevity and Seven Bridges Genomics.
Xennex has 1 investor. Key investors include Lineage Cell Therapeutics.
Yes. Xennex was acquired by Lineage Cell Therapeutics in April 2012.